Last year, the Trump administration essentially disbanded the National Vaccine Program Office, folding it into an office focused on infectious diseases. Then the COVID-19 pandemic hit. What does this mean for monitoring the safety of the soon-to-be-approved COVID-19 vaccines?
In less than two weeks, the Trump administration will have passed that magical “first 100 days” marker. Let’s check in and see how Donald Trump is shaping federal biomedical policy thus far. Hint: It’s deregulation über alles.
Here we go again. Every time I think I can get away from this topic for a while, I get sucked back in. Indeed, it seems that hardly a week can go by when I don’t find myself pulled inexorably back to this horrible, horrible clinic and what I consider to be the abuses of […]